Clinical stage biotechnology company within the therapeutic field of life-threatening fungal diseases Biosergen AB (STO:BIOSGN) announced on Friday that it has successfully completed the treatment of the first patient with BSG005, a promising candidate for addressing invasive fungal infections, which claim 2.5 million lives annually.

The first patient, a 47-year-old male with uncontrolled diabetes and Mucormycosis, showed significant improvement, avoiding the need for lung removal surgery and experiencing no major safety issues. BSG005, designed to be safe, effective, and broad-spectrum, is a critical development amid rising resistance to current therapies.

Five trial sites in India are now fully operational, with recruitment efforts ongoing despite challenges posed by stringent eligibility criteria. Alkem Laboratories Ltd, a top Indian pharmaceutical company, actively supports the trial and will finance future phases in India. The trial is expected to complete by January 2025, with the goal of improving survival rates in patients with resistant fungal infections. Biosergen plans to provide ongoing updates on patient outcomes.